Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Kane Biotech Inc. V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

Latest News

Kane Biotech to Host Investor Webinar


Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products


Emerging opportunity in a growing, high-value dermatological market


Canadian Investment Regulatory Organization Trade Resumption - KNE


Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health


Canadian Investment Regulatory Organization Trading Halt - KNE


Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results


Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health


Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024...


Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award


Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair


Kane Biotech Files New Patent on revyve(TM) Antimicrobial Wound Gel Spray


Kane Biotech to Present its revyve(TM) Antimicrobial Wound Gel at Boswick Burn and Wound Care...


Kane Biotech Announces Special Meeting of Shareholders


Kane Biotech Announces Correction to Press Release